Similarly, recent studies have suggested that AML patients with concomitant DNMT3A R882+/FLT3-ITD+/NPM1+ mutations had a very poor prognosis, and allo-HSCT could moderately improve their survival [62, 63]. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.